PJBioPharmaSolutions.com 

PJ BioPharma Solutions Satisfied Clients (1)
Paul carefully listens to the client needs and designs a unique analytical, strategic or partnering plan, adding others to the consulting team as needed, to provide a customized complete business solution. 

He is proud of the projects completed for the highly satisfied clients below.
Excalliard Pharmaceuticals
Paul collaborated with market research colleagues to complete a market analysis and sales forecasts for a new scar healing product. He then revamped the pitch presentation for potential partner companies to explain the true value of the product in the desired target patient population. This supported negotiations with potential partner companies and resulted in Excalliard being acquired by Pfizer for $75 million.
https://investors.pfizer.com/investor-news/press-release-details/2011/Pfizer-to-Acquire-Excaliard-Pharmaceuticals/default.aspx
Pozen (subsequently Aralez Pharmaceuticals)
A series of possible in-licensing and acquisition candidates were assessed to build the value of the Pozen product portfolio. Market analyses and sales forecasts were prepared. However, Paul identified key strategic considerations which were beyond the original project scope but led to Pozen’s senior leadership recognizing the acquisitions were outside the company’s expertise, a poor fit with the existing business and would not add the value anticipated. Hence the project was appropriately abandoned.
With colleagues in the field, Paul completed a comprehensive landscape review of the future market for psychedelic medicines. The project specifically delivered an analysis of the opportunities and obstacles in gaining market success and reimbursement for MDMA, combined with psychotherapy, to deliver a remarkable new therapy for PTSD.
MAPS Public Benefit Corporation   (https://mapspublicbenefit.com/)
Novo Nordisk
Paul was a keynote speaker during the Novo Nordisk’s 2020 GO CV Summit, a virtual global conference for the company’s marketing and sales leaders around the globe. The lecture and Q&A was created in collaboration with the company to share key strategies for success in gaining access to global cardiology market customers.